CCCC
C4 Therapeutics, Inc.
There isn't enough reported data to score CCCC yet.
CCCC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CCCC's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CCCC PE Valuation
CCCC has no meaningful PE right now: it lost money over the past year.
CCCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CCCC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
CCCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$1.05 |
| Q2 2026 | -$0.91 | +$0.68 |
| Q1 2026 | -$1.10 | +$0.38 |
| Q4 2025 | -$1.27 | +$0.25 |
| Q3 2025 | -$1.68 | +$0.02 |
| Q2 2025 | -$1.59 | +$0.31 |
| Q1 2025 | -$1.48 | +$0.89 |
| Q4 2024 | -$1.52 | +$1.15 |
CCCC is still losing money, but far less than before: $0.63 per share over the past year, against $8.62 at its worst in early 2020.
CCCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.5M | -25% |
| Q2 2026 | $6.6M | +2.8% |
| Q1 2026 | $6.2M | -15% |
| Q4 2025 | $11M | +113% |
| Q3 2025 | $11.2M | -27% |
| Q2 2025 | $6.5M | -46% |
| Q1 2025 | $7.2M | +138% |
| Q4 2024 | $5.2M | +59% |
CCCC's revenue is growing: $8M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -290% | +16 points |
| Q2 2026 | -398% | +43 points |
| Q1 2026 | -452% | -49 points |
| Q4 2025 | -210% | +518 points |
| Q3 2025 | -306% | -123 points |
| Q2 2025 | -441% | -262 points |
| Q1 2025 | -403% | +657 points |
| Q4 2024 | -728% | +419 points |
CCCC's operating margin was −290% last quarter, up 16 points from the same quarter a year ago.
CCCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26M | +$5.7M |
| Q1 2026 | -$30M | +$3.3M |
| Q4 2025 | -$22.2M | -$4.2M |
| Q1 2025 | -$33.3M | -$15.2M |
| Q4 2024 | -$17.9M | +$6.2M |
| Q1 2024 | -$18.1M | +$15.6M |
| Q4 2023 | -$24.2M | +$6.5M |
| Q1 2023 | -$33.7M | -$6.9M |
CCCC has burned cash in almost every quarter: −$80M over the past year, against −$101M the year before.
CCCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +5.4M shares |
| 1 year | +88% | +63.5M shares |
| 3 years | +177% | +87M shares |
| 5 years | +210% | +92.2M shares |
| Available history | +690% | +119M shares |
CCCC has 136M diluted shares, up 88% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $39,000 |
| Q2 2026 | — |
| Q1 2026 | $200,000 |
| Q4 2025 | $14,000 |
| Q3 2025 | $24,000 |
| Q2 2025 | — |
| Q1 2025 | $155,000 |
| Q4 2024 | — |
CCCC has spent almost nothing on buybacks in the past year.
CCCC Net Leverage
CCCC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CCCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 27.4 | Neutral |
CCCC's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
CCCC PE vs Healthcare Sector
CCCC has no meaningful PE right now: it lost money over the past year.
CCCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.02 | 8.3% below |
| 20 week MA | $3.48 | 20% below |
| 50 week MA | $3.07 | 9.8% below |
| 100 week MA | $2.72 | 1.8% above |
| 200 week MA | $3.77 | 27% below |
CCCC's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
CCCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $35.4 | +39% |
| 2021 | $35.4 | $33.4 | -5.8% |
| 2022 | $33.4 | $6.08 | -82% |
| 2023 | $6.08 | $5.65 | -7.1% |
| 2024 | $5.65 | $3.79 | -33% |
| 2025 | $3.79 | $2.12 | -44% |
| 2026 YTD | $2.12 | $2.77 | +31% |
CCCC has finished five years in a row lower, and it's up 31% so far in 2026.